Ecuador Plans Multi-Country Drug Imports to Ease Public Hospital Shortages

Media partner

POLICY & MARKETS · SEPTEMBER 12, 2026 · LATIN AMERICA

Shortages of medicines in Ecuador’s public hospitals have grown acute enough that President Daniel Noboa is pursuing government-to-government procurement deals with four countries at once. On July 27, 2026, Noboa confirmed that his administration is in active talks with Colombia, India, Argentina, and Costa Rica to purchase medicines for state-run health facilities, according to statements carried by EFE and reported by Infobae. The announcement follows a May 24, 2026 pledge — made during Noboa’s annual address to the nation — of a forthcoming ‘gran compra de medicinas’ (large medicine purchase) to address shortages that have drawn sustained public criticism.

The structural driver is a supply chain under simultaneous pressure from two directions. Ecuador imports 99% of its medical supplies, including equipment, reagents, and devices, according to Asedim, the Asociación Ecuatoriana de Distribuidores e Importadores de Productos Médicos (Ecuador’s association of medical product distributors and importers). Of that total, 15% originates in Colombia. A trade dispute between the two countries has compounded pre-existing shortages: Ecuador imposed tariffs on Colombian goods, and the consequences have been sharpest in dialysis units, where roughly 70% of consumables — filters, solutions, catheters — depend on Colombian supply, per Asedim figures cited by El País. The per-kit cost for dialysis supplies has risen from $20 to $50, according to El País, a level that Cristina Murgueitio, Asedim’s representative, described as ‘impossible’ to absorb at a 50% tariff rate.

Noboa’s framing of the initiative carries a deliberate pricing rationale. He stated that private importers who ‘wanted to charge crazy prices’ would lose their pricing leverage once government-to-government channels are established, according to the EFE report. That framing positions the procurement shift not merely as a supply diversification exercise but as an attempt to restructure the price-setting dynamic in Ecuador’s public pharmaceutical market — a market where the state is both the principal buyer and the entity that fixes acquisition prices for public facilities.

The regulatory pathway is uneven across the four supplier countries. For India, Noboa confirmed that a ‘roadmap’ has been established with the Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (Arcsa), Ecuador’s medicines regulatory authority, and that homologation is already in process. He specified that Indian medicines will carry United States Food and Drug Administration (FDA) certification, and that a parallel track is being developed to validate European certifications. For Colombia, Argentina, and Costa Rica, Noboa confirmed that conversations are underway but provided no equivalent detail on regulatory timelines or certification frameworks, according to the Infobae report. The announcement does not specify which medicines are included in the Colombia, Argentina, or Costa Rica discussions.

The Confederación Nacional de Salud, Ecuador’s national health confederation, has introduced a condition that could slow execution regardless of diplomatic progress. Following Noboa’s May announcement on India, the confederation publicly demanded that the government disclose the specific laboratories involved, the manufacturing certifications backing each product, and evidence of compliance with good manufacturing practices before any distribution to patients, according to Infobae. The confederation stated that the origin country alone is an insufficient criterion and that quality-assurance documentation must be made public. That demand has not been resolved in the public record, and Arcsa has not confirmed a timeline for completing homologation reviews for any of the four supplier countries.

For pharmaceutical manufacturers in Colombia, Argentina, and Costa Rica — countries Noboa described as having ‘fairly advanced’ pharmaceutical industries — the opening appears commercially real but operationally contingent. A government-to-government framework, if executed, would bypass the private import channels that currently set prices, potentially offering manufacturers direct access to Ecuador’s public procurement tenders. The size of the addressable procurement pool has not been disclosed in available public sources. What is structurally relevant is the sequencing risk: Arcsa’s homologation process for India is already running, giving Indian suppliers a regulatory head start over regional competitors whose certification pathways have not yet been formally initiated, at least not in the public record.

The trade dispute with Colombia adds a layer of political complexity that the procurement announcement does not resolve. Ecuador’s tariff on Colombian goods — which reached 50% according to El País — remains in place, and the Asedim representative noted an existing ‘millionaire debt’ owed by the state to dialysis clinics, a liability that predates the tariff escalation. Noboa’s government had not responded to Asedim’s request for a meeting with the vice-president as of the El País report in March 2026. Reopening Colombian pharmaceutical supply through a government-to-government channel while the broader tariff dispute remains unresolved introduces a negotiating complexity that the available record does not address.

The deeper tension in Noboa’s strategy is that the same regulatory apparatus — Arcsa’s homologation process — that is meant to guarantee medicine quality is also the principal bottleneck between a diplomatic announcement and a functioning supply chain. Diplomatic progress and regulatory throughput are running on separate clocks, and the patients currently waiting for dialysis supplies are exposed to the gap between them.